摘要
1995～ 1998三年中 ,对绝经期骨质疏松 (MOP) 111例进行为期 2年的前瞻性雌激素替代治疗 (HRT)研究 ,其中 56人应用利维爱 (Livial)为研究组 ,55人应用尼尔雌醇为对照组 ,经过 2年随诊 ,终点结论是 HRT对缓解更年期症状 ,提高患者生活质量 ,增加骨密度 (BMD)都有效果 ,但研究组明显优于对照组 ,具有统计学意义。 HRT的副作用为出血 :治疗组 5.35% ,对照组 10 .9% ,乳房胀痛 :治疗组7.14% ,对照组 9.0 9%。经济承受力差 ,中途退出治疗组 8.92 % ,对照组 3.6 3%。从而证实 L ivial作为HRT,对 MOF治疗的正作用强 ,副作用少 ,是 HRT首选药 ,今后如能降低药价 ,更适合我国医疗改革的国情 ,使患者经济承受力能够接受 ,将会在更多 MOR治疗中起到积极作用。
patients with postmenopausal osteoporosis received hormone replacement therapy (HRT) for three years (from 1995 to 1998). These patients were divided into two groups according to the drugs taken. One group of 56 women who took livial was regraded as study group, and the other group of 55 women who took nylestriol was regraded as control group. Both were observed for two years. The results showed that both drugs had certain effect on relieving climacteric syndrome,raising patient's living quality and increasing bone mineral density,but the result of bone mineral density in the study group was much better than that in the control group. Patients who withdrew from the study for untoward side effects or financial problem were more in number in the control group than in the study group. It is concluded that livial has a high efficacy on postmenopausal osteoporosis and less untoward effect; if its price goes cheaper,it might play a more important role in the therapy of postmenopausal osteoporosis.
出处
《中国骨质疏松杂志》
CAS
CSCD
2000年第2期48-51,共4页
Chinese Journal of Osteoporosis
